These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 975718)

  • 1. Protein binding of salicylate in uremic and normal plasma.
    Borgå O; Cederlöf IO; Ringberger VA; Norlin A
    Clin Pharmacol Ther; 1976 Oct; 20(4):464-75. PubMed ID: 975718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of chronic renal failure and hemodialysis on diflunisal plasma protein binding.
    Verbeeck RK; De Schepper PJ
    Clin Pharmacol Ther; 1980 May; 27(5):628-35. PubMed ID: 7371361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acid.
    Odar-Cederlöf I; Borga O
    Clin Pharmacol Ther; 1976 Jul; 20(1):36-47. PubMed ID: 1277724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of salicylate binding to synovial fluid and plasma protein in patients with rheumatoid arthritis.
    Trnavská Z; Trnavský K
    Eur J Clin Pharmacol; 1980 Nov; 18(5):403-6. PubMed ID: 7439262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma protein carbamylation and decreased acidic drug protein binding in uremia.
    Erill S; Calvo R; Carlos R
    Clin Pharmacol Ther; 1980 May; 27(5):612-8. PubMed ID: 7371359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of salicylate binding to normal plasma by extracts of uremic fluids.
    Roman S; Gulyassy PF; Depner TA
    Am J Kidney Dis; 1984 Sep; 4(2):153-61. PubMed ID: 6475946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salicylate clearance, the resultant of protein binding and metabolism.
    Furst DE; Tozer TN; Melmon KL
    Clin Pharmacol Ther; 1979 Sep; 26(3):380-9. PubMed ID: 466931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein binding of salicylate in cutaneous hepatic porphyria.
    Steele WH; Boobis SW; Moore MR; Goldberg A; Brodie MJ; Summer DJ
    Eur J Clin Pharmacol; 1978 Jun; 13(4):309-13. PubMed ID: 668790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction of protein binding defect in uremic sera by charcoal treatment.
    Craig WA; Evenson MA; Sarver KP; Wagnild JP
    J Lab Clin Med; 1976 Apr; 87(4):637-47. PubMed ID: 1270877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salicylate protein binding in serum from young and elderly subjects as measured by diafiltration.
    Lesko LJ; Narang PK; Yeager L; Cutler NR
    Eur J Clin Pharmacol; 1985; 28(3):339-45. PubMed ID: 4007039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum protein binding of salicylate during pregnancy and the puerperium.
    Lovecchio JL; Krasner J; Yaffe SJ
    Dev Pharmacol Ther; 1981; 2(3):172-9. PubMed ID: 7227142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbamazepine-salicylate interaction in normal and uremic sera: reduced interaction in uremic sera.
    Dasgupta A; Thompson WC
    Ther Drug Monit; 1995 Apr; 17(2):199-202. PubMed ID: 7624911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in sodium salicylate protein binding in serum and synovial fluid from patients with a knee effusion.
    Caillier I; Bannwarth B; Monot C; Lapicque F; Netter P; Gaucher A; Royer RJ
    Int J Clin Pharmacol Ther Toxicol; 1990 Jan; 28(1):7-13. PubMed ID: 2303312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of carbamylation of plasma proteins and competitive displacers on drug binding in uremia.
    Calvo R; Carlos R; Erill S
    Pharmacology; 1982; 24(4):248-52. PubMed ID: 7089046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concentration dependent plasma protein binding of salicylate in rheumatoid patients.
    Ekstrand R; Alvan G; Borga O
    Clin Pharmacokinet; 1979; 4(2):137-43. PubMed ID: 378501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrease of in vitro serum protein binding of salicylate in rheumatoid arthritis.
    Netter P; Monot C; Stalars MC; Mur JM; Royer RJ; Faure G; Pourel J; Martin J; Gaucher A
    Eur J Drug Metab Pharmacokinet; 1984; 9(2):109-16. PubMed ID: 6745302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein binding of salicylate and quinidine in plasma from patients with renal failure, chronic liver disease and chronic respiratory insufficiency.
    Pérez-Mateo M; Erill S
    Eur J Clin Pharmacol; 1977 Mar; 11(3):225-31. PubMed ID: 856605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease.
    Roberts MS; Rumble RH; Wanwimolruk S; Thomas D; Brooks PM
    Eur J Clin Pharmacol; 1983; 25(2):253-61. PubMed ID: 6628510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of uremia, hemodialysis, and nonesterified fatty acids on zomepirac plasma protein binding.
    Pritchard JF; O'Neill PJ; Affrime MB; Lowenthal DT
    Clin Pharmacol Ther; 1983 Nov; 34(5):681-8. PubMed ID: 6627828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model representation of salicylate pharmacokinetics using unbound plasma salicylate concentrations and metabolite urinary excretion rates following a single oral dose.
    Shen J; Wanwimolruk S; Purves RD; McQueen EG; Roberts MS
    J Pharmacokinet Biopharm; 1991 Oct; 19(5):575-95. PubMed ID: 1783992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.